title: Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
abstract: BACKGROUND
  Cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) has been recognized as a treatment option for pseudomyxoma peritonei. This study reports the survival outcomes, clinicopathological prognostic factors, and a learning curve from a single institution's experience.
  
  
  METHODS
  Patients with pseudomyxoma peritonei underwent CRS and PIC, which was comprised of hyperthermic intraperitoneal chemotherapy (HIPEC) and/or early postoperative intraperitoneal chemotherapy (EPIC), according to a standardized treatment protocol in our institution. Clinicopathological factors were analyzed to determine their prognostic value for survival using univariate and multivariate analysis. Time period comparison was performed to study the effect of a learning curve.
  
  
  RESULTS
  A total of 106 patients (43 men and 63 women) were treated. The mortality rate was 3% and severe morbidity rate was 49%. The median follow-up was 23 (range, 0-140) months. The overall median survival was 104 months with a 5-year survival rate of 75%. The progression-free survival was 40 months with a 1-year progression-free survival rate of 71%. Factors influencing survival include histopathological type of tumor, use of both HIPEC and EPIC, peritoneal cancer index, completeness of cytoreduction, and severe morbidity. The results demonstrate a learning curve where patients with a higher peritoneal cancer index (PCI) were treated, reduced amount of blood products required, more patients undergoing HIPEC and the combined HIPEC and EPIC, more redo-procedures performed, and a longer progression-free survival.
  
  
  CONCLUSIONS
  This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
authors.affiliation: Department of Surgery, St George Hospital, University of New South Wales, Sydney, NSW, Australia. chua.terence@yahoo.com.sg
authors.forename: Terence C
authors.initials: TC
authors.lastname: Chua
authors.forename: Tristan D
authors.initials: TD
authors.lastname: Yan
authors.forename: Michelle E
authors.initials: ME
authors.lastname: Smigielski
authors.forename: Katherine J
authors.initials: KJ
authors.lastname: Zhu
authors.forename: Keh M
authors.initials: KM
authors.lastname: Ng
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: David L
authors.initials: DL
authors.lastname: Morris
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care; D011379:Prognosis; D011553:Pseudomyxoma Peritonei / Q000401:mortality* / Q000601:surgery / Q000628:therapy*; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents